Diagnostic utility of C-reactive protein to albumin ratio as an early warning sign in hospitalized severe COVID-19 patients.
Albumins
/ metabolism
Biomarkers
/ metabolism
C-Reactive Protein
/ metabolism
COVID-19
/ diagnosis
Female
Hospitalization
Humans
Leukocyte Count
/ methods
Lymphocyte Count
/ methods
Male
Middle Aged
Neutrophils
/ metabolism
Prognosis
ROC Curve
Retrospective Studies
Risk Factors
SARS-CoV-2
/ pathogenicity
Severity of Illness Index
C-reactive protein to albumin ratio
COVID-19
SARS-CoV-2
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
23
10
2020
revised:
24
11
2020
accepted:
06
12
2020
pubmed:
22
12
2020
medline:
3
2
2021
entrez:
21
12
2020
Statut:
ppublish
Résumé
C-reactive protein-to-albumin ratio (CAR) has been used as an indicator of prognosis in various diseases. Here, we intended to assess the CAR's diagnostic power in early differentiation of hospitalized severe COVID-19 cases. In this retrospectively designed study, we evaluated 197 patients in total. They were divided into two groups based on their severity of COVID-19 as non-severe (n = 113) and severe (n = 84). The comparison of groups' demographic data, comorbidities, clinical symptoms, and laboratory test results were done. Laboratory data of the patients within the first 24 h after admission to the hospital were evaluated. The calculation of receiver operating characteristic (ROC) curve was used to determine the diagnostic power of CAR in differentiating severity of COVID-19. Independent risk factors predictive of COVID-19 severity were determined by using logistic regression analysis. Although lymphocyte count levels were lower, severe COVID-19 patients had higher mean age, higher levels of neutrophil count, CRP, aspartate aminotransferase (AST), ferritin, and prothrombin time (P < 0.05). Compared with non-severe patients (median, 0.23 [IQR = 0.07-1.56]), patients with severe COVID-19 had higher CAR levels (median, 1.66 [IQR = 0.50-3.35]; P < 0.001). Age (OR = 1.046, P = 0.003), CAR (OR = 1.264, P = 0.037), and AST (OR = 1.029, P = 0.037) were independent risk factors for severe COVID-19 based on the multivariate logistic regression analysis. ROC curve analysis assigned 0.9 as the cut-off value for CAR for differentiation of severe COVID-19 (area under the curve = 0.718, 69.1% sensitivity, 70.8% specificity, P < 0.001). CAR is a useful marker in early differentiation of severity in patients hospitalized due to COVID-19 that have longer hospital stay and higher mortality.
Identifiants
pubmed: 33348293
pii: S1567-5769(20)33752-8
doi: 10.1016/j.intimp.2020.107285
pmc: PMC7833970
pii:
doi:
Substances chimiques
Albumins
0
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107285Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
PLoS One. 2018 Jan 3;13(1):e0190410
pubmed: 29298330
Inflamm Res. 2006 May;55(5):216-20
pubmed: 16830109
J Surg Oncol. 2016 Dec;114(7):895-899
pubmed: 27696432
J Med Virol. 2020 Oct;92(10):2152-2158
pubmed: 32406952
J Clin Invest. 2003 Jun;111(12):1805-12
pubmed: 12813013
Sci China Life Sci. 2020 Nov;63(11):1678-1687
pubmed: 32567003
J Med Invest. 2014;61(3-4):361-8
pubmed: 25264055
Front Oncol. 2019 Feb 21;9:89
pubmed: 30847301
Onco Targets Ther. 2017 Nov 02;10:5255-5261
pubmed: 29138578
Clin Med (Lond). 2020 Sep;20(5):463-467
pubmed: 32934038
Int J Colorectal Dis. 2011 Apr;26(4):473-81
pubmed: 21190025
Front Med (Lausanne). 2020 Nov 03;7:566591
pubmed: 33224959
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Med (Lond). 2009 Feb;9(1):30-3
pubmed: 19271597
Am J Med. 2017 Dec;130(12):1465.e11-1465.e19
pubmed: 28803138
J Med Virol. 2020 Jul;92(7):856-862
pubmed: 32281668
J Clin Virol. 2020 Jun;127:104364
pubmed: 32311650
Mol Psychiatry. 2020 Jun;25(6):1301-1311
pubmed: 29895893
Ann Surg Oncol. 2015 Mar;22(3):803-10
pubmed: 25190127
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
Int J Infect Dis. 2020 May;94:128-132
pubmed: 32251805
Front Immunol. 2018 Apr 13;9:754
pubmed: 29706967
JAMA Neurol. 2017 Jun 1;74(6):660-667
pubmed: 28384752
Med Mal Infect. 2020 Jun;50(4):332-334
pubmed: 32243911
PLoS One. 2013;8(3):e59321
pubmed: 23555017